Gene:
FLT4
fms-related tyrosine kinase 4

PharmGKB contains no dosing guidelines for this . To report known genotype-based dosing guidelines, or if you are interested in developing guidelines, click here.

PharmGKB has no annotated drug labels with pharmacogenomic information for this . If you know of a drug label with PGx, send us a message.

PharmGKB contains no Clinical Variants that meet the highest level of criteria.

Disclaimer: The PharmGKB's clinical annotations reflect expert consensus based on clinical evidence and peer-reviewed literature available at the time they are written and are intended only to assist clinicians in decision-making and to identify questions for further research. New evidence may have emerged since the time an annotation was submitted to the PharmGKB. The annotations are limited in scope and are not applicable to interventions or diseases that are not specifically identified.

The annotations do not account for individual variations among patients, and cannot be considered inclusive of all proper methods of care or exclusive of other treatments. It remains the responsibility of the health-care provider to determine the best course of treatment for a patient. Adherence to any guideline is voluntary, with the ultimate determination regarding its application to be made solely by the clinician and the patient. PharmGKB assumes no responsibility for any injury or damage to persons or property arising out of or related to any use of the PharmGKB clinical annotations, or for any errors or omissions.

? = Mouse-over for quick help

This is a non-comprehensive list of genetic tests with pharmacogenetics relevance, typically submitted by the manufacturer and manually curated by PharmGKB. The information listed is provided for educational purposes only and does not constitute an endorsement of any listed test or manufacturer.

A more complete listing of genetic tests is found at the Genetic Testing Registry (GTR).

PGx Test Variants Assayed Related Drugs?

The table below contains information about pharmacogenomic variants on PharmGKB. Please follow the link in the "Variant" column for more information about a particular variant. Each link in the "Variant" column leads to the corresponding PharmGKB Variant Page. The Variant Page contains summary data, including PharmGKB manually curated information about variant-drug pairs based on individual PubMed publications. The PMIDs for these PubMed publications can be found on the Variant Page.

The tags in the first column of the table indicate what type of information can be found on the corresponding Variant Page on the appropriate tab.

Links in the "Drugs" column lead to PharmGKB Drug Pages.

Variant?
(138)
Alternate Names / Tag SNPs ? Drugs ? Alleles ?
(+ chr strand)
Function ? Amino Acid?
Translation
No VIP available No Clinical Annotations available VA
rs307805 -942A>G, 180077487T>C, 24888760T>C, 4138A>G
T > C
5' Flanking
No VIP available No Clinical Annotations available VA
rs307821 180030313C>A, 24841586C>A, 3971G>T, 51312G>T, Arg1324Leu
C > A
Missense
Arg1324Leu
No VIP available No Clinical Annotations available VA
rs307822 *1475A>G, 180028717T>C, 24839990T>C, 52908A>G
T > C
3' UTR
No VIP available No Clinical Annotations available VA
rs307826 1480A>G, 180051003T>C, 24862276T>C, 30622A>G, Thr494Ala
T > C
Missense
Thr494Ala
No VIP available No Clinical Annotations available VA
rs6877011 *721G>C, 180029471C>G, 24840744C>G, 52154G>C
C > G
3' UTR
Alleles, Functions, and Amino Acid Translations are all sourced from dbSNP 138

Overview

Alternate Names:  None
Alternate Symbols:  PCL; VEGFR3
PharmGKB Accession Id: PA28183

Details

Cytogenetic Location: chr5 : q35.3 - q35.3
GP mRNA Boundary: chr5 : 180028506 - 180076624
GP Gene Boundary: chr5 : 180025506 - 180086624
Strand: minus
The mRNA boundaries are calculated using the gene's default feature set from NCBI, mapped onto the UCSC Golden Path. PharmGKB sets gene boundaries by expanding the mRNA boundaries by no less than 10,000 bases upstream (5') and 3,000 bases downstream (3') to allow for potential regulatory regions.

Curated Information ?

Curated Information ?

Curated Information ?

Publications related to FLT4: 3

No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Tumor angiogenesis genotyping and efficacy of first-line chemotherapy in metastatic gastric cancer patients. Pharmacogenomics. 2013. Scartozzi Mario, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
VEGF pathway polymorphisms as prognostic and pharmacogenetic factors in cancer: a 2013 update. Pharmacogenomics. 2013. Eng Lawson, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Single nucleotide polymorphism associations with response and toxic effects in patients with advanced renal-cell carcinoma treated with first-line sunitinib: a multicentre, observational, prospective study. The lancet oncology. 2011. Garcia-Donas Jesus, et al. PubMed

LinkOuts

Entrez Gene:
2324
OMIM:
136352
153100
602089
UCSC Genome Browser:
NM_002020
RefSeq RNA:
NM_002020
NM_182925
RefSeq Protein:
NP_002011
NP_891555
RefSeq DNA:
AC_000048
AC_000137
NC_000005
NG_011536
NT_023133
NW_001838967
NW_922818
HuGE:
FLT4
Comparative Toxicogenomics Database:
2324
ModBase:
P35916
HumanCyc Gene:
HS00523
HGNC:
3767

Common Searches